SG Americas Securities LLC Has $157,000 Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)

SG Americas Securities LLC raised its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 106.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,706 shares of the biotechnology company’s stock after acquiring an additional 14,272 shares during the quarter. SG Americas Securities LLC’s holdings in Anavex Life Sciences were worth $157,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of AVXL. Fiduciary Alliance LLC bought a new stake in shares of Anavex Life Sciences during the 1st quarter valued at about $67,000. EntryPoint Capital LLC lifted its stake in Anavex Life Sciences by 371.1% in the first quarter. EntryPoint Capital LLC now owns 20,007 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 15,760 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Anavex Life Sciences by 8.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock worth $129,000 after buying an additional 2,401 shares in the last quarter. Saxon Interests Inc. acquired a new stake in shares of Anavex Life Sciences during the 1st quarter worth approximately $136,000. Finally, Marshall Wace LLP bought a new stake in shares of Anavex Life Sciences in the 2nd quarter valued at $166,000. Institutional investors own 31.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AVXL shares. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a research note on Friday, October 18th. EF Hutton Acquisition Co. I upgraded shares of Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd.

Anavex Life Sciences Stock Performance

Shares of NASDAQ:AVXL opened at $5.33 on Friday. Anavex Life Sciences Corp. has a 52-week low of $3.25 and a 52-week high of $10.45. The business’s 50 day simple moving average is $5.61 and its two-hundred day simple moving average is $4.98. The firm has a market cap of $451.14 million, a P/E ratio of -10.66 and a beta of 0.61.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same period in the prior year, the firm earned ($0.14) earnings per share. On average, equities analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current fiscal year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.